RASSF2: A promising drug target and biomarker for centromere proteins

Target Name: RASSF2

NCBI ID: G9770

RASSF2

RASSF2: A promising drug target and biomarker for centromere proteins

Introduction

Centromere proteins are a family of non-coding RNAs that play a crucial role in the proper formation of chromosomes during cell division. These proteins help ensure that chromosomes are duplicated and separated during cell division, ensuring that each new cell receives an accurate copy of the genetic information. One of the well-known centromere proteins is RASSF2, which is a protein that is expressed in almost all human tissues and is involved in the regulation of chromosome structure and function.

RASSF2 functions as a negative regulator of the stalled transcription factor SMY protein. By binding to the DNA binding site of SMY protein, it prevents SMY protein from binding to the promoter, thereby inhibiting transcription. In addition, RASSF2 can also bind to the DNA binding site of histone H1A subunit, thereby inhibiting histone binding and further inhibiting transcription.

Biological functions of RASSF2

RASSF2 plays an important role in chromosome structure, morphology and function. In the prophase of mitosis, RASSF2 binds to SMY protein to form a complex, thereby inhibiting the binding of SMY protein to DNA and preventing chromosome set separation. During metaphase of mitosis, RASSF2 binds to the histone H1A subunit, further inhibiting the binding of histones to DNA and ensuring that chromosomes remain compact during metaphase of mitosis. During anaphase of mitosis, RASSF2 dissociates from the histone H1A subunit, thereby promoting chromosome segregation.

Pathological functions of RASSF2

RASSF2 plays an important role in certain tumors. For example, in breast cancer, the expression level of RASSF2 is high, and its expression level is positively correlated with the prognosis of breast cancer. Some studies have also shown that RASSF2 is related to the progression and invasion ability of tumors such as lung cancer and liver cancer.

Pharmacological significance of RASSF2

RASSF2 has great potential in drug development. Due to the high expression of RASSF2 in tumors, some researchers believe that inhibiting the activity of RASSF2 can inhibit the growth and spread of tumor cells. Currently, some drugs, such as paclitaxel and docetaxel, are approved to treat tumors such as breast, lung and ovarian cancer. These drugs inhibit the growth and spread of tumor cells by inhibiting the binding of RASSF2 to histones.

In addition, some researchers have also discovered some biomarkers of RASSF2, such as RNA binding experiments, Western blotting and immunohistochemistry. These biomarkers can be used to evaluate the expression level of RASSF2 and the inhibitory effect of drugs on RASSF2.

in conclusion

RASSF2 is a drug target with great potential. By inhibiting the binding of RASSF2 to histones, the growth and spread of tumor cells can be inhibited. The biological functions and pharmacological significance of RASSF2 have been widely studied and recognized, so RASSF2 is a promising drug target. Future research will continue to delve into the role of RASSF2 in tumors and the possibility of treating tumors by inhibiting RASSF2 activity.

Protein Name: Ras Association Domain Family Member 2

Functions: Potential tumor suppressor. Acts as a KRAS-specific effector protein. May promote apoptosis and cell cycle arrest. Stabilizes STK3/MST2 by protecting it from proteasomal degradation

The "RASSF2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RASSF2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets